Maypharm Lifesciences Private Limited’s Post

Please join me for a conversation today with the 5 leaders of our Indian Pharma industry

💊 𝗚𝗘𝗡𝗘𝗥𝗜𝗖𝗦 𝗜𝗡 𝟮𝟬𝟮𝟰 - 𝗧𝗛𝗘 𝗥𝗢𝗔𝗗 𝗦𝗢 𝗙𝗔𝗥💊 A few weeks ago I kickstarted my survey in understanding talent acquisition in the context of the #generics market of this year - and after chatting to experts at various levels across commercial teams in the UK, I reached a few conclusions about the overall state of the market. Do you agree? Let me know below👇 Teva Pharmaceuticals Cipla Kent Pharma UK Ltd Accord Healthcare ADVANZ PHARMA Aspire Pharma Ltd AUROBINDO PHARMA LTD Bowmed Ibisqus Limited B. Braun Group Brown & Burk UK Ltd (BBUK) Colonis Pharma Ethypharm Bristol Laboratories Ltd. Consilient Health Dexcel Pharma Dr. Reddy's Laboratories Fresenius Kabi GENESIS Pharma Glenmark Pharmaceuticals hameln pharma gmbh Jubilant Pharma Limited Lupin SUN PHARMA Morningside Healthcare Ltd Niche Generics Limited Piramal Group RIVOPHARM Rosemont Pharmaceuticals Sandoz Viatris Thornton & Ross Wockhardt Ltd. Zentiva #pharma #marketresearch #markettrends #hiring

Speaking at the panel discussion on “Decoding the path to progress” at #AhmedabadPharmaSummit 2024, Dr. Mahesh Bhalgat highlighted the importance of effective leadership strategies in the dynamic landscape of healthcare. He also narrated how Indian CROs including Veeda Clinical Research Limited play a crucial role in addressing regulatory complexities and challenges by leveraging technology that enables efficient data collection, storage, and analysis, leading to better decision-making and insights. Veeda is focusing on building new-age capacities and capabilities that involve integrating technologies, fostering innovation and developing specialized expertise to meet the evolving needs of clients and the industry.   https://lnkd.in/dXTHaNqE

In November, I had the opportunity to speak with Rhonda Duffy, COO, Biocon Biologics, at CPHI & PMEC India about the challenges in the Indian pharmaceutical sector. She shared valuable insights into what the country needs to do to strengthen its position as a global pharma hub. Duffy said, “What we must get right about India is reliability. It’s about getting ourselves to a standard, keeping that standard, and proving we are a reliable supplier.” Key takeaways from our conversation include: 📌 The importance of leadership development across all levels – from shop floors to C-suites. 📌 The need for Indian pharma companies to embrace strategic partnerships and collaborate meaningfully. 📌 Addressing gaps in infrastructure and government support to promote Indian pharma globally. India has the talent, potential, and ambition. The question is: Can we bring it all together to cement our place in the global pharma landscape? Read to find more:

Gaining significant influence in the Indian pharmaceutical scene of the 1960s, we now meet Cipla in the 70s. By this point, the company has introduced over 30 APIs*. It has also expanded its horizons into new areas, including manufacturing and pioneering more effective drug delivery methods. Approaching its golden jubilee in 1985, Cipla, under the leadership of Dr. Y.K. Hamied committed itself to a future defined by innovation. By prioritising manufacturing, research and development, the company aimed to set new benchmarks in pharmaceutical excellence. 17th August 1985 – the company celebrates its Golden Jubilee and there’s so much to be jubilant about. This era, a special time in #TheCiplaStory, is filled with several significant milestones and steady growth.   •A New Identity Is Born: The company’s name, The Chemical, Industrial & Pharmaceutical Laboratories was formally registered as Cipla Limited in 1984, with a new logo to match •US FDA Approvals: Cipla's Vikhroli, Bangalore, and Patalganga plants were among India's first to secure USFDA approval for API manufacturing, a testament to the company’s stringent quality standards. •Manufacturing Excellence: By implementing advanced manufacturing processes and rigorous GMP practices across all facilities, Cipla transformed scientific knowledge into industrial success. •Specialising in Therapies: Setting high standards of quality in diverse areas like anti-infectives, cardiac, and respiratory drugs, Cipla played a pivotal role in elevating India's pharmaceutical industry to global prominence.   Archival photographs: Cipla Archives | Photographs of factory sites: Amit Pasricha   For an immersive dive into our illustrious legacy, do follow Cipla Archives on Instagram: https://lnkd.in/diwUY9_C   #89YearsofCipla #StrongLegacyStrongerFuture #LegacyofCare #CiplaArchives #BusinessArchives #CorporateHistory #FromTheArchives

Major Transformation Alert in Indian Pharma! At the recent USA-India Chamber of Commerce meeting in Boston, Dilip Shanghvi, MD of Sun Pharma, shared some exciting developments in the Indian pharmaceutical industry. From being recognized primarily as a generic drug producer, India is pivoting towards becoming a hub for high-value innovative products. With substantial investments in science and advanced technologies, the landscape is expected to transform visibly in the next 2-3 years. Sun Pharma is leading the charge with a pipeline of over 10 specialty and innovative drugs in the US, achieved through strategic acquisitions and building skilled commercial teams. This shift isn't just about Sun Pharma. It's a collective move with Indian giants like Dr. Reddy's, Glenmark, Lupin, Biocon, and Zydus investing heavily in innovative research. The road has been challenging with setbacks, but the potential for significant returns on these long-term investments is immense. As the global pharma landscape evolves, the changes are not just in production but in the mindset. The notion that "if another Indian company can do it, we can too" is propelling Indian companies towards groundbreaking innovations. For more insights into this transformation and to understand how this impacts global healthcare, follow the latest updates. #Pharmaceuticals #Innovation #SunPharma #Healthcare #Biotech #Leadership

I am deeply appreciative of the heartfelt reception to my previous post, prompting me to share this subsequent post with you all. Continuing on my personal odyssey through the realm of pharmaceutical victories. #Post-2 🚀✨ Behold, within these unspoken words lies a tale of triumph and success waiting to be revealed! 🌿💊 🏢 From Humble Beginnings to Global Success: The Inspiring Journey of Aurobindo Pharmaceuticals Ltd. 🌏💡 🌱 Founded in 1986 by Dr. Ramprasad Reddy and Dr. K. Nityananda Reddy, Aurobindo Pharma started its journey with a small team and a big dream. 🚀 Milestones Achieved: - In the early 1990s, Aurobindo Pharma made its mark by becoming one of the first Indian pharmaceutical companies to receive WHO-GMP certification for its manufacturing facilities. - By the mid-2000s, the company expanded its footprint globally, setting up subsidiaries and acquiring companies to strengthen its presence in key markets. - In 2017, Aurobindo Pharma entered the prestigious list of the top 10 generic companies worldwide, a testament to its commitment to quality and affordability. - Fast forward to 2024, Aurobindo Pharma continues to innovate and grow, with a diverse product portfolio spanning multiple therapeutic areas and a robust pipeline of new products. 🌟 Key Success Factors: - Embracing cutting-edge technology and research to deliver groundbreaking pharmaceutical solutions. - Fostering a culture of excellence, integrity, and customer-centricity at every step. - Strategic partnerships and acquisitions that have propelled the company to new heights. 🔮 Future Growth: - Committed to continuous innovation and R&D to address evolving healthcare needs. - Expanding into new markets and therapeutic areas to reach even more patients. - Driving sustainable growth while upholding the values that have defined Aurobindo Pharma's success story. 🌿 Join us in celebrating the phenomenal growth journey of Aurobindo Pharmaceuticals Ltd.! 🎉💼 #AurobindoPharma #HealthcareInnovations #GlobalSuccess #PharmaceuticalIndustry #GrowthStory 🌏🔬

UBS on Pharma Sector Sun Pharma – Initiate Buy with TP of Rs 2450 Cipla – Initiate Buy with TP of Rs 2060 Zydus Life – Initiate Sell with TP of Rs 850 Dr Reddy – Initiate Sell with TP of Rs 5700 Aurobindo – Initiate Sell with TP of Rs 1333 Lupin – Initiate Sell with TP of Rs 2250 Trends weakening in India, US Street under-appreciating growth slowdown in both India and the US India: unbranded generics are 25%+ of urban and 35%+ of non-urban markets US generic market is declining: >50% of US branded market shifted to biologics Balance sheets and FCF are healthy and would help in diversification #Pharma #India #US #DrReddy #ZydusLife #SunPharma #Lupin #Aurobindo #Cipla

AUROBINDO PHARMA LTD's Stellar Surge: #Net #Profit #Soars by 79.6% in Q4 2024 Here is the Quick #Summary #RevenueResurgence Aurobindo Pharma showcases a 17.1% YoY revenue increase to Rs 7,580 Crore, signaling robust market performance. #EBITDAMargins The company reports an EBITDA margin of 22.3%, reflecting efficient operations and profitability. #NetProfitGrowth A significant 79.6% YoY net profit growth to Rs 909 Crore, even after a one-time exceptional loss, demonstrates financial strength. #StrategicInvestments With the commercialization of four manufacturing plants and advancements in biosimilars, Aurobindo Pharma emphasizes its commitment to innovation and expansion. #CashFlowAndInvestments The company maintains a healthy financial position with a Free Cash Flow of 12 Mn US$ and net cash including investments of approximately US$ 18 Mn AUROBINDO PHARMA LTD Aurobindo Pharma Malta Ltd Aurobindo Pharma USA, Inc. For more Information: https://lnkd.in/grGgvxSG -PP Prathyusha Pitta. Ph.D., MBA #PPInsights #AurobindoPharma #FinancialHealth #RevenueGrowth #EBITDASuccess #NetProfitSurge #StrategicExpansion #InnovationInvestment #ManufacturingMilestones #BiosimilarsProgress #CashFlowOptimization #InvestorRelations #Pharmaceuticals #MarketPerformance #BusinessGrowth #FinancialFortitude #LIPostingChallengeIndia #EY #EYParthenon #consulting #pharma #womeninconsulting #consultants #businessadvisory #strategyconsulting #healthcare #pharmaceuticals #healthcareconsulting #businessstrategy #managementconsulting #womenleaders #womenempowerment #genderdiversity #professionalwomen #careerdevelopment #leadership #womeninbusiness #consultingfirm #businessconsulting #pharmaceuticalindustry #consultinglife #careeradvice #workplaceequality #diversityandinclusion #womeninleadership #consultingworld 

#pharmaindustry update > As many as 15 blockbuster drugs whose revenues worth USD 112 billion will be off patented during 2023 to 2029. > The Indian pharma industry will have a growth opportunity of USD 10 billion in the form of generics (including complex). > Indian pharma exports recorded 8.85% growth during April and May this year at USD 4.73 billion against USD 4.35 billion during the same period last fiscal. > With the advent of quality concerns raised by global regulatory agencies, Pharmexcil’s priority has been shifted to quality management and imbibing quality culture in the industry. > India has 748 US Food and Drug Administration approved manufacturing facilities. > Indian pharma exports grew from USD 3.9 billion in FY05 to USD 27.85 billion in FY24 and is expected to touch around USD 31 billion this fiscal. > Latin America and Africa are the focused geographies for Indian pharma exports. Anamind has been working with major global #pharma companies to support in their #scmplanning processes and helping them adopt best practices in planning across the globe. To know more do visit our website www.anamind.com or connect with us to know more. SUN PHARMA Abbott Pfizer West-Coast Pharma GSK AUROBINDO PHARMA LTD AstraZeneca Johnson & Johnson Novartis Merck Cipla Dr. Reddy's Laboratories Zydus Group MANKIND PHARMA LTD Torrent Pharmaceuticals Ltd Lupin Pharmaceuticals Alkem Laboratories Ltd. Biocon Sheetal Yadav Prabir Mukherjee Warambo Jane Rutger Nouwen Meghanath Reddy Gaurav Mohanty Parikshit Br Vivian Viegas Shwetha Sharath Riya Srivastava Shristi Raj Aditi Kulkarni Mannatil Geetha Deepa Seshan Praveen Kumar Rishi Trivedi